I’m surmising that other trial sites, if there are any, will also be in Eastern Europe. This is a pretty safe bet insofar as reputable clinicians in the US and Western Europe would not enroll their HCV patients in such a trial.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”